Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/15/2021 | $6.00 → $5.50 | Buy | Aegis Capital | |
| 7/28/2021 | $6.00 | Buy | Aegis Capital |
4 - Presidio Property Trust, Inc. (0001080657) (Issuer)
4 - Presidio Property Trust, Inc. (0001080657) (Issuer)
4 - Presidio Property Trust, Inc. (0001080657) (Issuer)
Aegis Capital reiterated coverage of Presidio Property Trust with a rating of Buy and set a new price target of $5.50 from $6.00 previously
Aegis Capital initiated coverage of Presidio Property Trust with a rating of Buy and set a new price target of $6.00
424B5 - CDT Equity Inc. (0001896212) (Filer)
NT 10-K - CDT Equity Inc. (0001896212) (Filer)
8-K - Presidio Property Trust, Inc. (0001080657) (Filer)
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced the filing of two new patent applications that further expand the Company's intellectual property portfolio surrounding tapinarof, a drug currently approved for the treatment of psoriasis and atopic dermatitis. The first newly filed patent covers a combination therapy pairing tapinarof with a class of drugs clinically proven in psoriasis and atopic dermatitis, while the second patent relates to novel cocrystal forms of tapinarof with these agents. CDT believes these developments may underpin a second-generation tapinarof product with enhance
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") announces that its board of directors has approved a 1-for-25 reverse stock split of the Company's common stock. The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios. The reverse stock split will become effective on March 26, 2026, at 5:00 pm, Eastern Time (the "Effective Time"), and the Company's common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market ("Nasdaq") at market open under the existing
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 23, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announces that it has completed initial signature mapping of its asset portfolio against Sarborg Limited's recently curated rare disease database, identifying multiple high-potential opportunities across a range of rare and underserved indications. The analysis, conducted using Sarborg's proprietary AI Signature Agent platform, evaluated CDT's portfolio of assets, including its solid-form patent portfolio and its licensed AstraZeneca compounds AZD1656 and AZD5658, against a database of approximately 1,700 rare disease signatures. The Company reports t
4 - CDT Equity Inc. (0001896212) (Issuer)
3 - CDT Equity Inc. (0001896212) (Issuer)
4 - CDT Equity Inc. (0001896212) (Issuer)
SC 13G/A - Presidio Property Trust, Inc. (0001080657) (Subject)
SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, today announces the appointment of Simon Fry to its Board of Directors. Mr. Fry has over 30 years' experience in investment banking having held senior executive positions at various top-tier in
SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) (the "Company" or "Conduit"), today announced the Company is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on Friday, May 24th, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automat
SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc. ("Presidio" or the "Company"), an internally managed, diversified real estate investment trust ("REIT"), announced today that it has entered into a cooperation agreement with Zuma Capital Management, LLC ("Zuma"), Ouray Capital Management, LLC ("Ouray"), Reuben Berman, Stefani Carter, Vito Garfi, Brent Morrison, Elena Piliptchak, and certain affiliated and associated persons thereof (collectively, the "Zuma Investor Group") that beneficially holds, in the aggregate, 1,103,655 shares, or approximately 7.6%, of Presidio's outstanding common stock. Under the terms of the cooperation agreement, Elena Piliptchak, the
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has entered into a strategic transaction to acquire a 20% equity stake in Sarborg Limited ("Sarborg"), an agentic AI signature intelligence business operating across multiple industrial sectors. The investment formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT's clinical assets through Sarborg's proprietary signature analysis and artificial intelligence capabilities. Sarborg's business is built on the principle that biological, chemical and industrial signatures
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 17, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced the acquisition of 9.25648743 Bitcoin ("BTC") for an aggregate purchase price of $1,005,000 (gross of fees), at an average acquisition price of $108,301.75 per BTC. Following this transaction, CDT's total Bitcoin holdings now stand at 17.9090111 BTC. This acquisition marks a continued execution of CDT's cryptocurrency treasury reserve strategy, aimed at diversifying the Company's balance sheet and enhancing long-term shareholder value through the prudent accumulation of digital assets. "CDT remains committed to strategically deploying capita
SAN DIEGO, July 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:SQFT, SQFTP, SQFTW)) Presidio Property Trust, Inc. ("Presidio" or the "Company"), an internally managed, diversified real estate investment trust ("REIT"), today announced that its Board of Directors has authorized, and the Company has declared, a dividend on its 9.375% Series D Cumulative Redeemable Perpetual Preferred Stock (the "Series D Preferred Stock") for the months of July 2025, August 2025 and September 2025. In accordance with the terms of the Series D Preferred Stock, the July 2025 Series D dividend will be payable in cash in the amount of $0.19531 per share on August 15, 2025, to shareholders of record of Series D Pref